03.13.24
Biotech company Revance Therapeutics has promoted Conor Gallagher, PhD, to the role of chief scientific officer.
Dr. Gallagher joined Revance in April 2018 to lead the medical affairs group. Over the past few years, he expanded his role to oversee R&D, process and analytical development under the umbrella of scientific innovation. Additionally, he leads Revance's team working on the biosimilar program.
Prior to joining Revance, Dr. Gallagher spent 12 years at Allergan in medical affairs roles of increasing responsibility. He received his PhD in neuroscience from the University of Toronto.